Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD
Recruitment status was Recruiting
To determine the glucose regulation status of patients who were suspected to have CAD in central Taiwan.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Screen of Diabetes Mellitus by Oral Glucose Tolerance Test in Subjects Receiving Catheterization or Multi-detector Computed Tomography (MDCT) for Coronary Artery Disease|
- HbA1c and results of meal tolerance test [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]Patient who was diagnosed with DM after an OGTT was asked to follow up HbA1c after 6-12 months. Acarbose was given for those who had HbA1c > 6.5%. After 26 weeks, sitagliptin was given for those who had HbA1c > 7.0%.
- Hypoglycemia [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]Symptoms of hypoglycemia or glucose value below 70 mg/dl after treatment with acarbose
|Study Start Date:||April 2009|
|Estimated Study Completion Date:||December 2011|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Acarbose for DM patient with HbA1c > 6.5%. Add on sitagliptin if HbA1c > 7.0% after 26 weeks.
Acarbose 25 mg tid, titrate to 100 mg tid.
Other Name: Glucobay
It had been reported that high prevalence of IGT and unknwon DM in patients with CAD. This study aimed to determine the glucose regulation status of patients who were suspected to have CAD in central Taiwan. In general, patient who were admitted for CAG or MDCT without known DM were eligible. After informed consent, OGTT was performed to determine the glucose regulation status. Patients who were diagnosed as new DM would be asked to follow up after 6-12 months with diet control. Treatment with oral anti-diabetic drug may be needed if HbA1c target was not reached.
|Taichung Veterans General Hospital||Recruiting|
|Taichung, Taiwan, 40705|
|Contact: Wayne H-H Sheu, MD, PHD email@example.com|
|Principal Investigator:||Wayne H-H Sheu, MD, PHD||Taichung Veterans General Hospital|